A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Andrea E. Wahner Hendrickson et al.|Clinical Cancer Research|2024Cited by 15
Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0
Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0
Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0
Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0